| 107.02 -1.3 (-1.2%) | 07-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 139.62 | 1-year : | 163.07 |
| Resists | First : | 119.54 | Second : | 139.62 |
| Pivot price | 110.44  |
|||
| Supports | First : | 103.7 |
Second : | 93.91 |
| MAs | MA(5) : | 108.54 |
MA(20) : | 108.43 |
| MA(100) : | 125.85 |
MA(250) : | 145.81 |
|
| MACD | MACD : | 0.8 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 30 |
D(3) : | 37.4 |
| RSI | RSI(14): 47.5 |
|||
| 52-week | High : | 212.75 | Low : | 90.38 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ INSM ] has closed above bottom band by 27.6%. Bollinger Bands are 42.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 109.57 - 110.1 | 110.1 - 110.63 |
| Low: | 105.06 - 105.73 | 105.73 - 106.39 |
| Close: | 105.79 - 106.84 | 106.84 - 107.88 |
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Tue, 21 Jul 2026
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Tue, 21 Jul 2026
INSM Initiated Coverage by BMO Capital -- Price Target Announced at $192 - GuruFocus
Tue, 21 Jul 2026
Is Insmed (INSM) Priced Too Richly For Its Phase 3 Progress? - Yahoo Finance
Tue, 21 Jul 2026
Insmed (INSM) Following TPIP 12 Month Data, Does The Valuation Still Stack Up - Yahoo Finance UK
Mon, 20 Jul 2026
BMO initiates Insmed stock with outperform rating on respiratory franchise potential - Investing.com
Mon, 20 Jul 2026
Investors’ Concerns Hurt Insmed Incorporated (INSM) Despite Better-Than-Expected Results - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 217 (M) |
| Shares Float | 198 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 103.6 (%) |
| Shares Short | 16,030 (K) |
| Shares Short P.Month | 19,130 (K) |
| EPS | -5.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.25 |
| Profit Margin | -144.5 % |
| Operating Margin | -65.5 % |
| Return on Assets (ttm) | -31.2 % |
| Return on Equity (ttm) | -294.5 % |
| Qtrly Rev. Growth | 229.6 % |
| Gross Profit (p.s.) | 3.09 |
| Sales Per Share | 3.78 |
| EBITDA (p.s.) | -4.38 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -896 (M) |
| Levered Free Cash Flow | -606 (M) |
| PE Ratio | -19.01 |
| PEG Ratio | 1 |
| Price to Book value | 32.82 |
| Price to Sales | 28.3 |
| Price to Cash Flow | -25.9 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|